Magnesium Toxicity in Severe Pre-eclampsia
A 26-year-old primigravida at 34 weeks’ gestation is admitted with severe pre-eclampsia: BP 168/112 mmHg, 3+ proteinuria, headache, and visual flashes. She is started on magnesium sulfate 4 g IV over 20 minutes followed by 1 g/hour. Twelve hours later, she becomes drowsy. Deep tendon reflexes are absent, respiratory rate 8/min, oxygen saturation 91% on room air, and urine output 20 mL/hour over the last 3 hours. Serum magnesium 7.8 mEq/L (therapeutic 4–7 mEq/L), creatinine 1.3 mg/dL, platelets 98,000/µL. The infusion is still running at 1 g/hour. The nurse asks whether to increase the rate because the patient’s blood pressure is 158/100 mmHg and whether the drowsiness is from pre-eclampsia. The fetal heart rate tracing shows a baseline of 150 beats/min with reduced variability.
1. Is the drowsiness due to pre-eclampsia or magnesium toxicity? Justify your answer with the clinical and laboratory findings.
Read the worked answer
The findings point to magnesium toxicity rather than worsening pre-eclampsia. Pre-eclampsia can cause headache, visual disturbance and drowsiness, but it does not typically cause absent deep tendon reflexes and respiratory depression. This patient has a therapeutic-to-toxic magnesium level of 7.8 mEq/L, absent reflexes, a respiratory rate of 8/min, oxygen saturation of 91%, and oliguria. Magnesium is cleared renally, and her urine output of 20 mL/hour with creatinine 1.3 mg/dL means accumulation is likely.
The reduced fetal heart rate variability is also consistent with maternal magnesium effect and possible fetal compromise from reduced placental perfusion; it is not explained by the blood pressure alone. The infusion must be stopped immediately while the obstetric and critical care teams are called. Increasing the rate to treat BP would be dangerous - magnesium sulfate is for seizure prophylaxis, not blood pressure control.
2. Outline the immediate management, including drug doses and monitoring.
Read the worked answer
Stop the magnesium sulfate infusion at once. Call for senior obstetric, anaesthetic and critical care help. Give intravenous calcium gluconate 10% 10 mL (1 g) over 10 minutes as the specific antidote; repeat if there is no clinical improvement, and use calcium chloride only through a central line if gluconate is unavailable. Apply oxygen and monitor respiratory rate, oxygen saturation, deep tendon reflexes, urine output, ECG and level of consciousness. Be prepared to support ventilation if respiratory depression progresses.
Check arterial blood gases, magnesium, potassium, creatinine and calcium. Treat hypertension separately with intravenous labetalol or hydralazine according to protocol, not by increasing magnesium. If oliguria persists or the patient remains unstable despite calcium, arrange urgent dialysis because magnesium is dialysable. After recovery, restart magnesium only at a reduced dose with frequent reflex and respiratory monitoring, or use an alternative anticonvulsant if magnesium toxicity recurs.
3. How should magnesium sulfate be prescribed and monitored on the ward to prevent recurrence?
Read the worked answer
Prescribe a clear weight-independent regimen: 4 g loading dose over 20 minutes, then 1 g/hour maintenance. Before each hourly check, document deep tendon reflexes, respiratory rate, urine output and oxygen saturation. Continue only if reflexes are present, respiratory rate is above 12/min, and urine output is at least 25 mL/hour (or 0.5 mL/kg/hour). In renal impairment, reduce the maintenance rate and check serum magnesium rather than relying on clinical signs alone.
Avoid concomitant nephrotoxins and review all medicines for respiratory depressants. Do not titrate magnesium against blood pressure; use antihypertensives for BP control. Monitor the fetus with cardiotocography and involve senior staff early if variability remains reduced. Document the toxic episode clearly, and at any future pregnancy use a lower maintenance dose with a lower threshold for checking magnesium levels.